moxifloxacin has been researched along with ertapenem in 20 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (ertapenem) | Trials (ertapenem) | Recent Studies (post-2010) (ertapenem) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 850 | 89 | 485 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouza, E; Cercenado, E; Cuevas, O; Marín, M; Martínez-Alarcón, J; Sánchez-Martínez, M | 1 |
| Finegold, SM; Golan, Y; Goldstein, EJ; Gorbach, SL; Harrell, LJ; Hecht, DW; Jacobus, NV; Jenkins, SG; McDermott, LA; Pierson, C; Rihs, J; Ruthazer, R; Snydman, DR; Venezia, R; Yu, V | 1 |
| Bryk, A; Kanervo-Nordström, A; Könönen, E; Niemi, P | 1 |
| Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Goldstein, EJ | 1 |
| Karpov, OI; Strekachev, AIu; Zaĭtsev, AA | 1 |
| Engler, C; Harris, P; Norton, R | 1 |
| Dalhoff, A; Schubert, S | 1 |
| Alder, J; Arvis, P; De Waele, JJ; Hampel, B; Jensen, M; Reimnitz, P; Tellado, JM | 1 |
| Bettoli, V; Join-Lambert, O; Nassif, A | 1 |
| Deeds, S; Levitt, DS; Mookherjee, S; Oakes, P | 1 |
| Cheng, A; Chuang, YC; Sheng, WH; Wang, JT; Yang, JJ | 1 |
| Deans, KJ; Minneci, PC | 1 |
| Aarnio, M; Grönroos, J; Haijanen, J; Hurme, S; Ilves, I; Laukkarinen, J; Löyttyniemi, E; Marttila, H; Mattila, A; Meriläinen, S; Nordström, P; Paajanen, H; Pinta, T; Rantanen, T; Rautio, T; Rintala, J; Salminen, P; Sävelä, EL; Savolainen, H; Sippola, S; Sippola, T; Tammilehto, V | 1 |
| Allen, GP; Deao, KM; Hill, SA; Schipelliti, SM; Tran, T | 1 |
3 review(s) available for moxifloxacin and ertapenem
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New approaches to antibacterial therapy of infections in the surgical practice].
Topics: Abdominal Abscess; Aza Compounds; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Cross Infection; Ertapenem; Fluoroquinolones; Humans; Lactams; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Surgical Wound Infection | 2003 |
Antibiotic Treatment of Hidradenitis Suppurativa.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Clindamycin; Drug Therapy, Combination; Ertapenem; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Imipenem; Maintenance Chemotherapy; Metronidazole; Moxifloxacin; Remission Induction; Rifampin | 2016 |
2 trial(s) available for moxifloxacin and ertapenem
| Article | Year |
|---|---|
Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Fluoroquinolones; Humans; Incidence; Intraabdominal Infections; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome | 2013 |
Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Appendectomy; Appendicitis; Drug Therapy, Combination; Ertapenem; Female; Follow-Up Studies; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Moxifloxacin; Tomography, X-Ray Computed; Young Adult | 2021 |
15 other study(ies) available for moxifloxacin and ertapenem
| Article | Year |
|---|---|
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Minocycline; Nocardia; Nocardia Infections; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline | 2007 |
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
Topics: Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Time Factors; United States | 2007 |
Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteremia; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Peptostreptococcus; Species Specificity | 2007 |
Antimicrobial susceptibilities and clinical sources of Dialister species.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Burkholderia pseudomallei; Carbapenems; Doripenem; Ertapenem; Fluoroquinolones; Humans; Melioidosis; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrat
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Load; Bacteroides fragilis; beta-Lactams; Colony Count, Microbial; Enterobacter cloacae; Enterococcus faecalis; Ertapenem; Escherichia coli; Fluoroquinolones; Humans; Imipenem; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Pancreas; Pancreatitis, Acute Necrotizing; Quinolines; Regression Analysis | 2012 |
What Are the Chances?
Topics: Aged, 80 and over; Anti-Bacterial Agents; Cognitive Dysfunction; Diagnosis, Differential; Ertapenem; Humans; Male; Moxifloxacin; Sleepiness | 2017 |
Impact of broad-spectrum antimicrobial treatment on the ecology of intestinal flora.
Topics: Acinetobacter baumannii; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Feces; Female; Fluoroquinolones; Gastrointestinal Microbiome; Humans; Male; Microbial Viability; Middle Aged; Moxifloxacin; Pseudomonas aeruginosa; Taiwan | 2018 |
Evolving Issues in the Use of Antibiotics for the Treatment of Uncomplicated Appendicitis.
Topics: Acute Disease; Anti-Bacterial Agents; Appendectomy; Appendicitis; Ertapenem; Humans; Levofloxacin; Moxifloxacin | 2021 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multiple, Bacterial; Ertapenem; Gentamicins; Gonorrhea; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Neisseria gonorrhoeae | 2021 |